Lead Candidate Spotlight Tiziana Life Sciences is actively developing intranasal foralumab, a fully human anti-CD3 monoclonal antibody, with recent Phase 2a MS data and ongoing presentations at major neuroscience events, presenting a clear door for collaborations, co-development, or sponsored research with immunotherapy specialists.

Strategic Focus The company concentrates on transformational immunomodulation therapies, indicating a potential opportunity to sell contract research, clinical trial services, or platform partnerships to accelerate trials in neurodegenerative and autoimmune indications.

Clinical Pipeline Momentum Frequent participation and visibility at high-profile industry events (BIO-Europe, Neuroscience Innovation Forum, ECTRIMS) signal active pipeline advancement and a need for supported clinical operations, regulatory consulting, and data management services.

Global Outreach With activities and announcements spanning international conferences and collaborations, there is potential to engage global CROs, manufacturing partners, and translational science experts to scale development and manufacturing of biologics and intranasal formulations.

Commercial Readiness Revenue scale is modest but growing; opportunities exist to discuss strategic commercialization services, market access partnerships, and payer strategy collaborations to prepare for future product launches.